Jeffrey Lipton

Nov 4, 2024 | onlinelibrary.wiley.com | Nihar R. Desai |Auro Viswabandya |Temerty Faculty |Jeffrey Lipton

Conflicts of Interest The authors declare no conflicts of interest. References 1, , , , and , “Post–Hematopoietic Stem Cell Transplantation Immune-Mediated Anemia: A Literature Review and Novel Therapeutics,” Blood Advances 6, no. 8 (2022): 2707–2721. 2, , , and , “Daratumumab for Delayed Red-Cell Engraftment After Allogeneic Transplantation,” New England Journal of Medicine 379, no. 19 (2018): 1846–1850.

Aug 15, 2024 | onlinelibrary.wiley.com | Jeffrey Lipton

To the Editor: In this issue of the American Journal of Hematology, there is an interesting analysis of a study involving an exciting, very effective newly marketed, targeted therapy for chronic myeloid leukemia (CML).1 The authors raise some interesting questions about utility and positioning of this drug in therapy. A quote from Warren Buffett, reputedly one of the 10 richest individuals in the world, is “Price is what you pay.

Mar 14, 2024 | onlinelibrary.wiley.com | Jeffrey Lipton

As with many haematological disorders, absence of a mechanistic understanding of Diamond–Blackfan anaemia (DBA) left clinicians with imperfect therapeutic options; red cell transfusions, corticosteroids and stem cell transplantation, derived from decades of anecdotal evidence. There is nothing mechanistic about providing red cells when none can be made.